Navigation Links
NeurogesX Reports Second Quarter 2009 Results
Date:8/7/2009

SAN MATEO, Calif., Aug. 7 /PRNewswire-FirstCall/ --

2Q09 Corporate Highlights:

  • Granted European Commission (EC) approval of Qutenza for treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain
  • Entered exclusive agreement with Astellas Pharma Europe Ltd. (Astellas) for commercialization of Qutenza in Europe, Middle East and Africa, including commercialization option and development funding for NGX-1998 and post-marketing studies to support Qutenza EU marketing efforts
  • Submitted results to FDA from FDA-requested Qutenza study (Study C123) in patients with PHN following pretreatment with FDA-approved topical anesthetic
  • Announced FDA orphan drug designation for Qutenza in PHN
  • Added to Russell 3000((R)) Index

Upcoming 2009 Milestones:

  • FDA PDUFA date of November 16, 2009, extended from August 16, 2009, for Qutenza NDA in PHN

NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today reported results for the second quarter ended June 30, 2009 and provided an update on recent accomplishments.

During the second quarter of 2009, the European Commission (EC) approved Qutenza in all 27 EU-member countries for the treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain. Following the approval, NeurogesX finalized an exclusive agreement with Astellas Pharma Europe Ltd. (Astellas) for the commercialization of Qutenza in the European Economic Area (EEA)
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. NeurogesX Announces New PDUFA Date for Qutenza(TM) New Drug Application
2. NeurogesX to Hold Conference Call to Discuss Second Quarter 2009 Financial Results
3. NeurogesX Added to Russell 3000 Index
4. NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
5. NeurogesX to Present at Needham Life Sciences Conference
6. NeurogesX Receives European Commission Approval for Qutenza(TM)
7. NeurogesX Reports First Quarter 2009 Results
8. NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results
9. NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
10. NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
11. NeurogesX Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...wire/ -- Veridiam (www.veridiam.com) won the prest...ory at the 2009 Workplace Excellence Awards. The a...uman Resources Management and recognize innovative...Veridiam was one of nine winners, selected from mo...at the recent awards ceremony. San Diego-based Ver...
(Date:11/20/2009)... Novavax, Inc. (Nasdaq: ...written public offering of 6,800,000 shares of its...r share. The approximately $21 million of net pro...and commissions, will be used for preclinical stud... internal research and development programs, worki...
(Date:11/20/2009)...wswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI)...inth Circuit Court of Appeals reversed a U.S. Dist...wed to pursue all of its claims against The Lash G...for trial. CTI filed a complaint against The Lash...sultant for CTI,s product TRISENOX, in 2007 seekin...
(Date:11/20/2009)...EDO recently announced that Dr. Dominique Hebrault...rocess Analytical Technology (PAT) in Green Chemis...09. , (PRWEB) November 20...al Technology (PAT) in Green Chemistry and Green E...cal Technology (PAT) case studies will be presente...
Breaking Biology Technology:Veridiam Wins Workplace Excellence Crystal Award in Mid-Size Company Category 2Novavax Prices Public Offering of Common Stock 2Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2Process Analytical Technology (PAT) in Green Chemistry and Green Engineering 2
...s introducing a new building control system, Facil...mpany,s Authorized Building Control Specialist (AB...hardware and software solution that is scalable to...hether large or small. It offers operators quick a...the company said. It also provides remote monitori...
...ban Madison will gain early review and easier acce...hat Wisconsin Alumni Research Foundation (WARF) ha...igned by the two parties, Promega announced Tues...from WARF , the agreement makes it easier to lice...ducts for the marketplace. , ,"There are multiple ...
... "biotech hotbed," the leader of a West Coast vent...atives in Wisconsin and other states in the region...r than its whole right now," said G. Steven Burril...ed firm whose principal activities are in venture ...on life sciences. "The Midwest is not the first pl...
Other Biology Technology:Promega to get early access to WARF technologies under new agreement 2Midwest called next 'biotech hotbed' 2Midwest called next 'biotech hotbed' 3Midwest called next 'biotech hotbed' 4
(Date:11/20/2009)...NN ARBOR, Mich.---We,ve all read studies about the...e thing is true at the molecular level, where amin...e to damage when single than when paired up with o...sity of Michigan, along with colleagues in Belgium...otects single cysteines. The research appears in t...
(Date:11/20/2009)...esearchers are invited to contribute their abstrac... WCO ECCEO10), the largest global meeting devoted... research and patient care. The Congress will be h...inning today, abstracts can be submitted online at...on deadline is February 4, 2010. , IOF and ESCEO...
(Date:11/20/2009)...orth Grafton, Mass., November 19, 2009 The estima...ndustry may be at risk of developing respiratory s...cording to a questionnaire study undertaken earlie... Cummings School of Veterinary Medicine. , The s...rn workersfound that 50 percent of individuals wor...
Breaking Biology News(10 mins):Saving the single cysteine: New antioxidant system found 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 3Barn personnel experience higher-than-average rates of respiratory symptoms 2Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference 14101 1MHA Announces Release of RxPertise 28TM 29 8 0 57386 1MHA Announces Release of RxPertise 28TM 29 8 0 57386 2Exercise Benefits Even the Oldest Old 57383 1Exercise Benefits Even the Oldest Old 57383 2
...illips will establish an eight-year, $22.5 million...ed to developing technologies that produce biorene...plan to create joint research programs with major ...ify America,s energy sources. , ConocoPhillips wi...upport Iowa State researchers, with additional gra...
...lion people die every year from respiratory diseas...particular, an infection can be dangerous. What is...is risk group as it is with younger people. The re...he immune system is reduced. Why this is the case ...d by the University of Bonn is now starting which ...
...xcessive doses of a common vitamin in an attempt t... the hospital—or worse. , Researchers from The Ch...ty of Pennsylvania reported on two adults and two ...aking large amounts of niacin, also known as vitam...ts. , Both adult patients suffered skin irrita...
Other Biology News:ConocoPhillips establishes $22.5M biofuels research program at Iowa State 2ConocoPhillips establishes $22.5M biofuels research program at Iowa State 3Fighting influenza & co. with 40,000 blood samples 2Fighting influenza & co. with 40,000 blood samples 3Misusing vitamin to foil drug test may be toxic; plus, it doesn't work 2
...all for critical, but time-consuming optimization ...es siRNA transfection protocols resulting in less ...n can be used to efficiently transfect adherent ce...otoxicity. From start to finish, successful gene s...
...s cerevisiae, as well as other yeasts, has become ...ratories. The ability to transform whole cells at ...ng lithium based buffers and polyethylene glycol h...y screening easy and reliable, especially when com...
...condary Detection System uses biotin-avidin-HRP co...e Primary Antibody. The primary antibody binds to ...ess antibody is removed by washing. Next, the Seco...dded and will react with the primary antibody pres...
...ers a wide range of hands-on techniques that are u...l areas of protein chemistry and molecular biology... just how valuable this book will be to your resea...al background of a method or group of related meth...
Biology Products: